Ipilimumab for Patients with Relapse after Allogeneic Transplantation

BACKGROUND: Loss of donor-mediated immune antitumor activity after allogeneic hematopoietic stem-cell transplantation (HSCT) permits relapse of hematologic cancers. We hypothesized that immune checkpoint blockade established by targeting cytotoxic T-lymphocyte–associated protein 4 with ipilimumab co...

Full description

Saved in:
Bibliographic Details
Published in:N Engl J Med
Main Authors: Davids, Matthew S., Kim, Haesook T., Bachireddy, Pavan, Costello, Caitlin, Liguori, Rebecca, Savell, Alexandra, Lukez, Alexander P., Avigan, David, Chen, Yi-Bin, McSweeney, Peter, LeBoeuf, Nicole R., Rooney, Michael S., Bowden, Michaela, Zhou, Chensheng W., Granter, Scott R., Hornick, Jason L., Rodig, Scott J., Hirakawa, Masahiro, Severgnini, Mariano, Hodi, F. Stephen, Wu, Catherine J., Ho, Vincent T., Cutler, Corey, Koreth, John, Alyea, Edwin P., Antin, Joseph H., Armand, Philippe, Streicher, Howard, Ball, Edward D., Ritz, Jerome, Bashey, Asad, Soiffer, Robert J.
Format: Artigo
Language:Inglês
Published: 2016
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5149459/
https://ncbi.nlm.nih.gov/pubmed/27410923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1601202
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items